Key Highlights

● Centene shares fell about 2.4% to $67.05, a day after beating earnings estimates.

● The company raised its 2026 adjusted earnings guidance by $0.40 per share.

● Its medical-cost ratio held steady at 92.7%, which some read as a mixed signal.

● Centene expects continued earnings growth into 2027 from a higher base.

Centene (NYSE:CNC) shares fell about 2.4% on October 28, 2026, closing at $67.05, a day after the company reported third-quarter results that beat earnings expectations and raised its full-year outlook. No new negative company announcement was identified for the session, and the decline looks like profit-taking after a strong year-to-date run combined with continued debate over the quality of the quarter.

Profit-Taking After a Guidance Raise

Centene posted total revenues of $50.6 billion for the quarter, with adjusted diluted earnings of $0.58 per share, up from $0.50 a year earlier and ahead of consensus. The company's consolidated health benefits ratio, a measure of medical costs relative to premium revenue, was 92.7%, unchanged from a year earlier; some analysts read that figure as weaker than hoped, while others viewed it as a modest improvement against their own estimates.

A Mixed Read on Medical Costs

Centene raised its 2026 adjusted earnings guidance by $0.40 per share, to more than $5.20, and narrowed its full-year health benefits ratio range. Management said its Marketplace business is on track for a pre-tax margin near the top of its target range, a turnaround from a negative margin a year earlier.

What Centene Does

Centene, based in St. Louis, is the largest US Medicaid managed-care company, serving about 11.9 million Medicaid members, along with roughly 3.4 million Affordable Care Act Marketplace members and a fast-growing Medicare and prescription drug plan business.

A Strong Quarter Meets a Cautious Market

The central risk for Centene remains Medicaid enrollment, which the company expects to decline further as states tighten eligibility checks, potentially leaving a sicker remaining population that could pressure margins unless states raise reimbursement rates accordingly.